AstraZeneca's Imfinzi (durvalumab) plus chemotherapy combo has received the European Medicines Agency’s (EMA) Committee for ...

EMA committee recommends approval of AstraZeneca’s Imfinzi in combo with chemotherapy to treat resectable non-small cell lung cancer ...

While the Oncologic Drugs Advisory Committee (ODAC) acknowledged that PD-L1 inhibitor Imfinzi (durvalumab) had met the efficacy objective in the AEGEAN trial that supported the application ...

AstraZeneca has announced that Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the ...

The similarly designed AEGEAN trial in lung cancer ran into that problem when it was discussed by an FDA advisory committee in July, where there was concern that there was no way to tell if post ...

Imfinzi in combination with chemotherapy has been recommended for approval in the European Union for the treatment of ...

AstraZeneca announced that a durvalumab (Imfinzi)-based perioperative regimen has been recommended by the EMA Committee for ...

The decision is supported by the outcomes from the AEGEAN trial. AstraZeneca oncology haematology research and development executive vice-president Susan Galbraith stated: “This recommendation ...

AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the European Union (EU) for the treatment of adults with resectable non-small cell lung cancer ...